Endologix, Inc. (ELGX) Reaches $3.98 After 3.00% Up Move; Tocagen (TOCA) Shorts Up By 0.74%

February 15, 2018 - By Adrian Erickson

The stock of Endologix, Inc. (NASDAQ:ELGX) is a huge mover today! The stock increased 5.01% or $0.19 during the last trading session, reaching $3.98. About 682,325 shares traded or 9.90% up from the average. Endologix, Inc. (NASDAQ:ELGX) has declined 63.00% since February 15, 2017 and is downtrending. It has underperformed by 79.70% the S&P500.The move comes after 7 months positive chart setup for the $332.15M company. It was reported on Feb, 15 by Barchart.com. We have $4.10 PT which if reached, will make NASDAQ:ELGX worth $9.96M more.

Tocagen Incorporated (NASDAQ:TOCA) had an increase of 0.74% in short interest. TOCA’s SI was 860,800 shares in February as released by FINRA. Its up 0.74% from 854,500 shares previously. With 167,400 avg volume, 5 days are for Tocagen Incorporated (NASDAQ:TOCA)’s short sellers to cover TOCA’s short positions. The stock decreased 0.33% or $0.04 during the last trading session, reaching $12.2. About 1,815 shares traded. Tocagen Inc. (NASDAQ:TOCA) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. The company has market cap of $241.68 million. The Company’s cancer-selective gene therapy platform is built on retroviral replicating vectors , which are designed to deliver therapeutic genes into the DNA of cancer cells. It currently has negative earnings. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG).

Among 10 analysts covering Endologix Inc. (NASDAQ:ELGX), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Endologix Inc. had 44 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Monday, October 2. Canaccord Genuity downgraded the stock to “Hold” rating in Thursday, November 17 report. The company was maintained on Monday, July 31 by RBC Capital Markets. The firm has “Overweight” rating given on Monday, April 4 by JP Morgan. The rating was downgraded by BMO Capital Markets on Tuesday, October 27 to “Market Perform”. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, February 23 report. Canaccord Genuity maintained the shares of ELGX in report on Thursday, August 17 with “Hold” rating. The stock has “Mkt Perform” rating by Leerink Swann on Tuesday, September 6. The firm earned “Hold” rating on Monday, September 25 by Canaccord Genuity. The firm has “Outperform” rating by RBC Capital Markets given on Monday, October 19.

Investors sentiment increased to 1.07 in 2017 Q3. Its up 0.25, from 0.82 in 2017Q2. It improved, as 21 investors sold Endologix, Inc. shares while 22 reduced holdings. 17 funds opened positions while 29 raised stakes. 83.13 million shares or 3.94% less from 86.54 million shares in 2017Q2 were reported. Wells Fargo Mn has 0% invested in Endologix, Inc. (NASDAQ:ELGX). Redmile Grp Llc holds 1.44% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 6.54M shares. The Georgia-based Voya Management Ltd Liability Corp has invested 0% in Endologix, Inc. (NASDAQ:ELGX). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 2,380 shares. Lombard Odier Asset Mgmt (Usa) owns 0.51% invested in Endologix, Inc. (NASDAQ:ELGX) for 1.60M shares. Cortina Asset Mgmt Limited Com holds 835,723 shares or 0.15% of its portfolio. Ubs Asset Mngmt Americas stated it has 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). Public Employees Retirement Association Of Colorado holds 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 20,710 shares. Bnp Paribas Arbitrage Sa stated it has 12,429 shares or 0% of all its holdings. Natixis holds 10,242 shares or 0% of its portfolio. 1.22 million are owned by Ny State Common Retirement Fund. State Street has invested 0% in Endologix, Inc. (NASDAQ:ELGX). 7,516 are held by Royal Fincl Bank Of Canada. Gam Ag holds 235,700 shares. Stoneridge Investment Ltd Liability Com reported 29,935 shares stake.

Analysts await Endologix, Inc. (NASDAQ:ELGX) to report earnings on February, 28. They expect $-0.22 EPS, 0.00% or $0.00 from last year’s $-0.22 per share. After $-0.11 actual EPS reported by Endologix, Inc. for the previous quarter, Wall Street now forecasts 100.00% negative EPS growth.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $332.15 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: